JP2016520595A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016520595A5 JP2016520595A5 JP2016515273A JP2016515273A JP2016520595A5 JP 2016520595 A5 JP2016520595 A5 JP 2016520595A5 JP 2016515273 A JP2016515273 A JP 2016515273A JP 2016515273 A JP2016515273 A JP 2016515273A JP 2016520595 A5 JP2016520595 A5 JP 2016520595A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- seq
- acid sequence
- chain variable
- variable region
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 34
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 13
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 13
- 239000000427 antigen Substances 0.000 claims 11
- 102000036639 antigens Human genes 0.000 claims 11
- 108091007433 antigens Proteins 0.000 claims 11
- 230000009977 dual effect Effects 0.000 claims 6
- 102100025248 C-X-C motif chemokine 10 Human genes 0.000 claims 4
- 208000026278 immune system disease Diseases 0.000 claims 4
- 101000858088 Homo sapiens C-X-C motif chemokine 10 Proteins 0.000 claims 3
- 206010039085 Rhinitis allergic Diseases 0.000 claims 3
- 201000010105 allergic rhinitis Diseases 0.000 claims 3
- 239000012634 fragment Substances 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 230000002265 prevention Effects 0.000 claims 3
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 2
- 239000013604 expression vector Substances 0.000 claims 2
- 102000040430 polynucleotide Human genes 0.000 claims 2
- 108091033319 polynucleotide Proteins 0.000 claims 2
- 239000002157 polynucleotide Substances 0.000 claims 2
- 238000002054 transplantation Methods 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 208000014181 Bronchial disease Diseases 0.000 claims 1
- 101710098275 C-X-C motif chemokine 10 Proteins 0.000 claims 1
- 201000004624 Dermatitis Diseases 0.000 claims 1
- 206010012438 Dermatitis atopic Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 201000008937 atopic dermatitis Diseases 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- 208000037979 autoimmune inflammatory disease Diseases 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 238000012761 co-transfection Methods 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000001963 growth medium Substances 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 230000000414 obstructive effect Effects 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20130057762 | 2013-05-22 | ||
| KR10-2013-0057762 | 2013-05-22 | ||
| KR20130057475 | 2013-05-22 | ||
| KR10-2013-0057475 | 2013-05-22 | ||
| PCT/KR2014/004579 WO2014189306A1 (ko) | 2013-05-22 | 2014-05-22 | 항 ＴＮＦ-α/ＣＸＣＬ10 이중 타겟 항체 및 그의 용도 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016520595A JP2016520595A (ja) | 2016-07-14 |
| JP2016520595A5 true JP2016520595A5 (OSRAM) | 2017-06-01 |
Family
ID=51933801
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016515273A Pending JP2016520595A (ja) | 2013-05-22 | 2014-05-22 | 抗ＴＮＦ−α／ＣＸＣＬ１０二重ターゲット抗体及びその用途 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US10087248B2 (OSRAM) |
| EP (1) | EP3000827B1 (OSRAM) |
| JP (1) | JP2016520595A (OSRAM) |
| KR (1) | KR101671955B1 (OSRAM) |
| CN (1) | CN105263964A (OSRAM) |
| AU (1) | AU2014269287B2 (OSRAM) |
| BR (1) | BR112015029224A2 (OSRAM) |
| CA (1) | CA2913118A1 (OSRAM) |
| HK (1) | HK1223112A1 (OSRAM) |
| PH (1) | PH12015502601A1 (OSRAM) |
| WO (1) | WO2014189306A1 (OSRAM) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112018076260A2 (pt) | 2016-06-20 | 2019-03-26 | Kymab Limited | anticorpo ou fragmento do mesmo que se liga especificamente a hpd-l1, anticorpo biespecífico ou proteína de fusão, uso de um anticorpo ou fragmento, método, composição farmacêutica, método de modulação, método de inibição, método de tratamento, ácido nucleico, vetor, hospedeiro e imunocitocina |
| EP3630836A1 (en) * | 2017-05-31 | 2020-04-08 | Elstar Therapeutics, Inc. | Multispecific molecules that bind to myeloproliferative leukemia (mpl) protein and uses thereof |
| WO2019197979A1 (en) * | 2018-04-10 | 2019-10-17 | Y-Biologics Inc. | Cell engaging binding molecules |
| US10640576B2 (en) | 2018-04-10 | 2020-05-05 | Y-Biologics Inc. | Cell engaging binding molecules |
| KR102088789B1 (ko) * | 2018-06-20 | 2020-03-13 | 인하대학교 산학협력단 | 항 TNF/IFN scFv-Fc 이중 표적 항체 및 이의 이용 |
| KR102323342B1 (ko) * | 2019-04-26 | 2021-11-08 | 주식회사 와이바이오로직스 | IL-17A 및 TNF-α에 특이적으로 결합하는 이중표적 항체 |
| KR102385046B1 (ko) | 2020-08-24 | 2022-04-13 | 에스큐엔지니어링(주) | 드론에 탈부착 점검장치를 이용한 다목적 구조물 검사장치 |
| US20240189423A1 (en) * | 2021-03-31 | 2024-06-13 | The Regents Of The University Of California | Bispecific binding agent-ligand fusions for the degradation of target proteins |
| KR102357756B1 (ko) | 2021-05-14 | 2022-02-09 | 유한회사 서해항공방제 | 드론을 이용한 유해 조수 및 곤충 방제장치 및 그를 구비하는 드론 |
| CN114432502B (zh) * | 2021-12-31 | 2023-02-03 | 中山大学附属第八医院（深圳福田） | 一种负载op3-4多肽、抗cxcl9抗体的水凝胶及其制备方法与应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69721548T2 (de) * | 1996-02-09 | 2004-04-01 | Abbott Laboratories(Bermuda)Ltd. | HUMANE ANTIKÖRPER WELCHE AN HUMANEN TNFalpha BINDEN |
| US20050053600A1 (en) * | 2003-09-09 | 2005-03-10 | Lane Thomas E. | Methods for treating rheumatoid arthritis |
| JP2008534508A (ja) | 2005-03-22 | 2008-08-28 | メドスター ヘルス インコーポレイテッド | 心血管疾患を診断および処置するための送達システムおよび方法 |
| BRPI0610058A2 (pt) * | 2005-05-16 | 2010-05-25 | Abbott Biotech Ltd | uso de inibidor de tnf para tratamento da poliartrite erosiva |
| JP2008543449A (ja) * | 2005-06-17 | 2008-12-04 | アボット・ラボラトリーズ | 変性脊椎疾患の改良型治療方法 |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| JP2012228248A (ja) * | 2005-08-19 | 2012-11-22 | Abbott Lab | 二重可変ドメイン免疫グロブリン及びその使用 |
| TWI323734B (en) * | 2005-08-19 | 2010-04-21 | Abbott Lab | Dual variable domain immunoglobulin and uses thereof |
| DE112008003232T5 (de) * | 2007-11-30 | 2011-02-24 | Glaxo Group Limited, Greenford | Antigen-Bindungskonstrukte |
| EP2519544A1 (en) * | 2009-12-29 | 2012-11-07 | Emergent Product Development Seattle, LLC | Polypeptide heterodimers and uses thereof |
| ES2971444T3 (es) * | 2011-10-11 | 2024-06-05 | F Hoffmann Lar Roche Ag | Ensamblaje mejorado de anticuerpos biespecíficos |
| KR20130121601A (ko) * | 2012-04-27 | 2013-11-06 | 주식회사에이앤알쎄라퓨틱스 | 인간 항 ｃｘｃｌ－１０ 항체 및 이를 포함하는 류마티스 관절염 치료용 조성물 |
-
2014
- 2014-05-22 JP JP2016515273A patent/JP2016520595A/ja active Pending
- 2014-05-22 KR KR1020140061598A patent/KR101671955B1/ko active Active
- 2014-05-22 EP EP14801159.6A patent/EP3000827B1/en active Active
- 2014-05-22 BR BR112015029224A patent/BR112015029224A2/pt not_active IP Right Cessation
- 2014-05-22 CA CA2913118A patent/CA2913118A1/en not_active Abandoned
- 2014-05-22 AU AU2014269287A patent/AU2014269287B2/en not_active Ceased
- 2014-05-22 CN CN201480029427.2A patent/CN105263964A/zh active Pending
- 2014-05-22 US US14/893,071 patent/US10087248B2/en active Active
- 2014-05-22 WO PCT/KR2014/004579 patent/WO2014189306A1/ko not_active Ceased
- 2014-05-22 HK HK16111369.2A patent/HK1223112A1/en unknown
-
2015
- 2015-11-23 PH PH12015502601A patent/PH12015502601A1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016520595A5 (OSRAM) | ||
| JP2022177090A5 (OSRAM) | ||
| JP2013542194A5 (OSRAM) | ||
| JP2014500009A5 (OSRAM) | ||
| JP2018521691A5 (OSRAM) | ||
| HRP20220811T1 (hr) | Agonistička sredstva za vezanje tnf receptora | |
| JP2018536393A5 (OSRAM) | ||
| RU2018106364A (ru) | Антитела против рецептора tfr и их применение при лечении пролиферативных и воспалительных расстройств | |
| JP2012116856A5 (OSRAM) | ||
| JP2018521638A5 (OSRAM) | ||
| JP2015533795A5 (OSRAM) | ||
| JP2015514110A5 (OSRAM) | ||
| JP2015503909A5 (OSRAM) | ||
| JP2013121353A5 (OSRAM) | ||
| JP2016538876A5 (OSRAM) | ||
| JP2020522280A5 (OSRAM) | ||
| JP2011502137A5 (OSRAM) | ||
| JP2011527899A5 (OSRAM) | ||
| JP2021500916A5 (OSRAM) | ||
| JP2020511946A5 (OSRAM) | ||
| SI2768859T1 (en) | Antagonists of il17c for the treatment of inflammatory disorders | |
| AR104906A1 (es) | Anticuerpos dirigidos a la proteína morfogenética ósea 9 (bmp9) y métodos a partir de estos | |
| JP2020522281A5 (OSRAM) | ||
| RU2014127287A (ru) | Антитела, используемые для пассивной вакцинации против гриппа | |
| RU2019111862A (ru) | Новые антитела против фактора xi и их применения |